头颈部鳞癌的综合治疗进展 - 肿瘤药学.pdf

-  - 肿瘤药学 2016 年 2 月第 6 卷第 1 期　Anti-tumor Pharmacy, February 2016, Vol. 6, No. 1 ●专　题● 头颈部鳞癌的综合治疗进展 李　芳，朱跃红 （湖南省肿瘤 医院/ 中南大学湘雅 医学院附属肿瘤 医院头颈肿瘤 内科 ，湖南　长沙， 100 1 ） 摘要：外科手术是头颈部鳞癌（HNSCC）的标准治疗方法，而晚期患者通过手术切除无法治愈，需要联合放疗、外 科手术及化疗。同步放化疗（CRT）被认为是标准的治疗方案，大量关于同步放化疗的临床研究试图寻找和证实最有效 的治疗方案，复发和治疗相关毒性是同步放化疗所面临的问题，西妥昔单抗和诱导化疗等治疗手段的发现为进一步控 制肿瘤复发和减轻治疗相关毒性提供了可能。本文就头颈部鳞癌的综合治疗进展作一综述。 关键词：头颈部鳞癌；放射治疗；化疗；分子靶向治疗 中图分类号： 文献标识码 ：A 文章编号：2095-1264（2016）01-04-05 doi：10.3969/j.issn.2095-1264.2016.01.01 Recent Advances in the Management of HNSCC LI Fang, ZH U Yuehong (Head and Neck Medical Oncology, Hunan Cancer Hosp ital the Aff iliated Cancer Hosp ital of Xiang Ya School of Medicine, Central South University, Changsha, Hunan, 410013, China) Abstract: Surgical management continues to be the standard of care for many head and neck squamous cell carcinoma (HNSCC). For patients with advanced disease not amenable to surgical resection.Various combinations of radiotherapy, surgery, and systemic therapy are generally required. Concurrent chemoradiotherapy (CRT) is now recognized worldwide as a standard treatment option. Evidence has largely supported the use of radiation treatment CRT, but disease recurrence and treatment toxicity continue to be chal- lenges with this treatment paradigm. To obtain improved outcomes and mitigate disease recurrence and treatment toxicity, new agents such as cetuximab and induction chemotherapy have been explored. This article is to review the recent advances in the management of HNSCC, including new developments in molecular biology and treatment. Key words: HNSCC; Radiotherapy; Chemotherapy; Molecular biology and treatment 前言